Sartorius AG ADR
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SOAGY research report →
Price Chart
About the company
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables.
- CEO
- Michael Grosse
- IPO
- 2024
- Employees
- 14,042
- HQ
- Göttingen, NI, DE
Get TickerSpark's AI analysis on SOAGY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $90.98B
- P/E
- 70.89
- PEG
- 2.40
- P/S
- 4.22
- P/B
- 5.27
- EV/EBITDA
- 17.73
- Div Yield
- 0.33%
- Gross Margin
- 45.43%
- Op Margin
- 17.81%
- Net Margin
- 5.96%
- ROE
- 7.81%
- ROIC
- 5.27%
Latest fiscal year · YoY change
- Revenue
- $3.40B+0.5%
- Gross Profit
- $1.57B+3.1%
- Op Income
- $625.69M
- Net Income
- $148.79M+77.1%
- EPS
- $0.43+77.9%
- OCF Growth
- -35.5%
- FCF Growth
- -63.7%
- 52W High
- $66.68
- 52W Low
- $46.97
- 50D MA
- $60.72
- 200D MA
- $54.93
- Beta
- 1.56
- RSI (14)
- 47
- Avg Volume
- 6.09K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sartorius said nine-month 2026 sales, margins, cash flow and deleveraging all improved, and it confirmed full-year guidance while lifting LPS expectations after a strong Q3.· October 22, 2026
- Group sales grew 6.9% in constant currencies in the first nine months, or 8.1% on an operational basis excluding tariff customer compensation.
- Underlying EBITDA rose 6.9% to EUR 828 million, with the group margin up 50 bps to 30.2%.
- Free cash flow increased 55% to EUR 310 million, helping net debt fall to EUR 3.68 billion and leverage improve to 3.3x.
- Bioprocess Solutions kept recovering, with operational sales up 8.1% in constant currencies and underlying EBITDA margin expanding to 32.3%.
- Lab Products & Services beat expectations, with operational sales up 8.3% in constant currencies and the full-year growth and margin outlook raised.
For the first nine months of 2026, group operational sales grew 8.1% in constant currencies excluding tariff-related customer compensation, or 6.9% including it. Underlying EBITDA increased 6.9% to EUR 828 million, and the underlying EBITDA margin expanded 50 basis points to 30.2%. Underlying EPS rose to EUR 3.76 per ordinary share and EUR 3.77 per preference share; reported net profit attributable to shareholders increased 51% to EUR 188 million. Operating cash flow rose to EUR 562 million and free cash flow climbed 55% to EUR 310 million. The company confirmed full-year guidance for group sales growth around the midpoint of its 5%-9% range and an underlying EBITDA margin slightly above 30%; BPS guidance was unchanged, while LPS growth guidance was raised to around the upper end of its 2%-6% range and its margin outlook was lifted to slightly above 21%.
Michael Grosse described the quarter as a solid nine-month performance with growth in both divisions, better profitability, strong cash flow and further deleveraging. He emphasized that end markets remain fundamentally intact, with healthy pipelines, rising research activity and continued recovery in bioprocess equipment, while also noting that AI-driven drug discovery is becoming more relevant for the lab business. He sounded confident but measured, saying Q3 strength should not be extrapolated into Q4 because of tougher comparisons, tariff headwinds and some pull-forward effects.
Florian Funck focused on the mechanics behind the numbers: tariff refunds of EUR 31 million were received in the first nine months against approximately EUR 40 million claimed, with the remaining EUR 9 million expected by year-end but timing uncertain. He cited group underlying EBITDA of EUR 828 million, LPS underlying EBITDA of EUR 114 million, operating cash flow of EUR 562 million, free cash flow of EUR 310 million and net debt of EUR 3.68 billion, with leverage improving to 3.3x. He also noted the CapEx ratio at 9.6% for the group and explained that tariff refunds and customer compensation offset each other on profitability, while improving balance sheet metrics reflect disciplined capital allocation.
Analysts pressed management on the sustainability of Bioprocess equipment recovery, AI-driven drug discovery benefits, U.S. reshoring, possible 5,000L single-use competition, and whether LPS’s strong Q3 was partly pull-forward. Management said equipment recovery is progressing steadily, with good visibility and strength in bioanalytics and desktop systems, but did not give a precise 2027 view. On AI, they said the benefit is mainly through more experiments, more data generation and more demand for instruments, consumables and services from biopharma and academia, while on LPS they said there was no single tender effect and the quarter was driven by recurring revenue, improving biotech funding and released CapEx.
The call pointed to broad-based demand improvement, with consumables still strong and equipment recovery continuing, especially in bioprocessing. Management also highlighted strong LPS momentum, AI-related workflow opportunities, improving cash generation and a stronger balance sheet, all while confirming full-year guidance and raising the LPS outlook.
Management repeatedly warned that Q3 included pull-forward/timing benefits in LPS and that Q4 faces a tough comparison base, so recent growth rates may not be repeatable. Tariff surcharges are now a headwind rather than a tailwind, there is uncertainty on the timing of remaining tariff refunds, and the company did not give a precise timeline for when equipment demand fully normalizes or how 2027-2028 demand will unfold.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 9.5%
- Shares Outstanding
- 1.46B
- Float Shares
- 138.08M
Congressional trading
Senate and House stock disclosures for SOAGY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Held by 3 ETFs
Biggest fund positions in SOAGY by dollar value.
Our SOAGY coverage
Recent articles, reports, and earnings notes.
No research on SOAGY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SOAGY report →Sartorius Aktiengesellschaft (SOAGY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 22
Sartorius Aktiengesellschaft Q3 Earnings Call Highlights
marketbeat.com · Oct 22
Sartorius Aktiengesellschaft (OTCMKTS:SOAGY) Stock Short Interest Rises 322.6%
defenseworld.net · Sep 25
Sartorius Aktiengesellschaft (SOAGY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 23
Sartorius Aktiengesellschaft (OTCMKTS:SOAGY) Short Interest Update
defenseworld.net · Jan 13
Sartorius Aktiengesellschaft (SOAGY) Q3 2025 Earnings Call Transcript
seekingalpha.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.